Johnson & Johnson's Caplyta meets primary endpoint in bipolar I mania trial
Tweet Send to a Friend
Johnson & Johnson (NYSE: JNJ) announced that its drug Caplyta (lumateperone) met the primary endpoint in a pivotal Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
